Pioneering 'Batman Procedure' Offers New Hope to High-Risk Heart Patients
New Delhi [India], August 8: Doctors at Rajasthan Hospital Limited (RHL), Jaipur have successfully performed India's first electrosurgical valve-in-valve mitral procedure, informally called the "Batman Procedure", giving a 74-year-old woman from Srinagar a new lease on life.
Fatima Bano, who had previously undergone open-heart surgery to replace two valves, was once again facing heart failure. Medical investigations revealed her mitral valve was failing, but her advanced age and health condition made her too high-risk for another conventional open-heart surgery, according to specialists at Srinagar and AIIMS, New Delhi. With her condition worsening and traditional surgery deemed too risky, her family turned to Dr. Ravinder Singh Rao, Chairman, RHL Heart Centre & Head - TAVI Program.
Dr. Rao and his team performed the complex procedure using an advanced electrosurgical technique. Using a minimally invasive catheter-based approach, Dr. Rao's team employed precision electrosurgical tools, including a fine electrified wire, to precisely open part of the malfunctioning mitral valve and implant a new one, all without opening the chest. This complex but swift procedure, rarely attempted in such high-risk patients, enabled Fatima to walk within days and return home to her routine life shortly after.
"This case proves that even elderly, high-risk patients can receive transformative treatment with the right tools and expertise," said Dr. Rao.
This case represents a significant milestone in India's cardiovascular care landscape: the nation's first electrosurgical valve-in-valve intervention for a failed mitral valve in a previously operated patient. The procedure demonstrates the possibility of safely treating complex heart valve disease in elderly, high-risk patients once deemed inoperable.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India Today
5 hours ago
- India Today
How safe are ‘natural' Ozempic alternatives in diabetes care?
It was late evening when Meera Rao sat at her kitchen table, surrounded by brightly coloured bottles—some labeled 'saffron blend', others 'organic GLP1 support'. The glossy covers promised safer, natural alternatives to GLP1 (glucagon-like peptide-1) drugs such as Ozempic, touting appetite control, gentle bloodsugar regulation and zero Rao, a 45-year-old homemaker in Noida, who had been recently diagnosed with prediabetes, felt overwhelmed. Should she trust a prescription GLP1 receptor agonist or experiment with a 'natural' dose?advertisementGLP1 is a gutderived hormone that enhances insulin secretion, curbs hunger and slows down digestion. Synthetic GLP1 receptor agonists—semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro)—have revolutionised diabetes and weightloss can induce up to 15–20 per cent bodyweight reduction while Mounjaro's launch in India has seen a sales surge, doubling in July 2025 alone to total over Rs 470 crore for 157,000 units sold. Unsurprisingly, India's GLP1 market, valued at about $106 million in 2023, is projected to expand nearly sixfold to $579 million by 2030. And India's broader diabetes care drugs market, ranging between $1.70 billion and $2.27 billion as of 2024-25, is expected to reach $2 billion-$ 3.7 billion by 2030. With over 74 million Indians already living with diabetes, projected to climb even higher in coming decades, the demand is the high cost and limited access to GLP1 injections drive a parallel boom: the rise of 'natural substitutes'. Products using naturally-derived ingredients are now being marketed to support GLP1 and GIP hormone pathways. With a polished label, 'natural' guarantee, a moneyback promise and five-star reviews, it lures hopeful consumers towards wellness narratives. Brand labels draped in pastel tones, slogans whispering 'organic, plantbased, gentle', and lifestyle images of yoga mats and herbal teas—all designed to feel less pharmaceutical and more holistic.A wave of 'gut-first' supplements are also being marketed as natural GLP-1 alternatives, aiming to mimic the hormone's appetite-suppressing and glucose-regulating effects. These products often combine ingredients like prebiotic fibers (inulin, psyllium), apple cider vinegar, cinnamon, berberine and probiotics to promote satiety, balance blood sugar and support insulin touted for mood and craving control, and glucomannan, a water-soluble fibre, are also being added to blends that promise to stimulate natural gut hormone responses. While the science behind gut health's role in metabolic regulation is evolving, most of these formulations lack the robust clinical data that GLP-1 drugs like Ozempic have, making them more supportive than substitutive in managing weight or substitutes, such as BRP, a natural peptide-based alternative to GLP1 drugs, are being researched upon as alternatives with less side-effects. Identified by researchers at Stanford via an AI-driven tool that sifted through thousands of potential hormone fragments, this peptide is taken from the BRINP2 protein through natural processing, and has been detected in biological samples including human cerebrospinal preclinical studies involving mice and mini pigs, BRP significantly suppressed appetite—reducing food intake by up to 50 per cent within an hour—and triggered fat-loss without any of the common side-effects associated with GLP1 drugs, such as nausea, digestive distress or muscle wasting. But its final efficacy will only come to light with human clinical studies and regulatory do they work as claimed? The evidence is thin. Experts caution that while supplements may support bloodsugar health modestly, they do not match the robust clinical results of GLP1 drugs. Weight-loss with supplements typically amounts to just onetofour pounds—compared to the doubledigit percentages achieved by prescription treatments. And because dietary supplements are less regulated, quality and safety vary widely. Some supplement lines position themselves as companions for GLP1 users—through a range of shakes and fibres to support those losing appetite and muscle mass on the medication itself. There is no harm in taking these alongside a prescribed medicine, say the lack of clinical proof, many like Rao continue to long for an easy, natural fix, but also fear complacency. In the end, Rao says she resolved to consult her physician, knowing that progress—not placebo—might require interventions that were clinical, not just India's rapidly shifting diabetes landscape, the allure of natural GLP1 alternatives is powerful, but careful awareness is essential. For all the pasteldraped promises, only proven therapies may offer more than to India Today Magazine- Ends
NDTV
13 hours ago
- NDTV
From Bat-Signal To Heart-Saver: How India's First Batman Procedure Helped A High-Risk Patient Avoid Open-Heart Surgery
Just ahead of India's 78th Independence Day, the nation has recorded its first electrosurgical valve-in-valve mitral procedure in August 2025-quite a milestone to be celebrated. A technically demanding transcatheter intervention was performed by a select team of doctors at Rajasthan Hospital, Jaipur for a 74-year-old woman with a failing mitral bioprosthesis. Heart valve disease remains a major but underdiagnosed health challenge among India's elderly population, particularly women. This breakthrough highlights the transformative potential of cutting-edge cardiac care for those with limited treatment options. The technique, informally dubbed the "Batman Procedure", used a catheter-based electrosurgical approach to treat a previously operated, high-risk patient without opening the chest, demonstrating a new option for selected inoperable cases. What does this mean for the future of heart health and surgeries in India, especially where making these procedures as minimally invasive as possible? We spoke to Dr. Ravinder Singh Rao, Chairman, RHL Heart Centre & Head - TAVI Program, the head of the team that successfully performed the Batman Procedure, to find out more. What Is The Batman Procedure And Why The Name? "The Batman Procedure refers to a minimally invasive, balloon-assisted intervention for complex mitral valve issues - especially when the mitral valve's anterior leaflet is severely damaged or cannot be repaired," explains Dr Ravinder Singh Rao. He adds that "the 'Batman' name comes from the visual of the inflated balloon in the aorta, which resembles the Bat-signal and helps control the blood flow while the damaged leaflet is treated." These electrosurgical techniques often use specialized electrified wires and laceration tools to modify native tissue or prior devices so a new valve can be implanted through a catheter route - in short, a hybrid of transcatheter valve-in-valve (ViV) ideas and targeted electrosurgery. Why This Is A Rare And Technically Complex Procedure Transcatheter mitral interventions remain among the most complex procedures in structural heart disease. As Dr Rao put it, the procedure is "exceptionally rare and technically demanding. It's only considered when traditional open-heart surgery is too risky or not feasible." The anatomy of the mitral valve, prior surgical repairs or replacements, and the risk of obstructing blood flow to the left ventricle make planning and execution exacting - requiring high-resolution imaging, experienced operators, and a coordinated heart health team. Electrosurgical modifications (for example, lacerating a tethered leaflet or cutting failed clips) have only recently moved from case reports and small series into selected clinical practice. The Jaipur Case: Batman Procedure To The Rescue According to the hospital summary, the 74-year-old patient had previously undergone dual valve replacement and then developed failure of the mitral bioprosthesis. Because her age and comorbid state made repeat open-heart surgery prohibitively risky, the team performed an electrosurgical valve-in-valve mitral implantation using a catheter-based approach. The patient walked within days and returned home soon after - an outcome that highlights the speed of recovery after percutaneous approaches compared with conventional redo sternotomy. "This case proves that even elderly, high-risk patients can receive transformative treatment with the right tools and expertise," Dr Rao said in a statement that underscores both the life-changing potential and the narrow indications for the technique. What Patients And Families Should Know The Batman Procedure is not a first-line therapy. It's reserved for highly selected patients, typically adults with prior valve surgery, failed repairs, or anatomy that makes repeat open surgery too dangerous. "It needs advanced infrastructure (sophisticated cath labs, specialized tools) and an expert team experienced in complex cardiac procedures," Dr Rao cautions, noting that "only a handful of Indian hospitals currently have these resources and capabilities." Post-procedure recovery is usually faster than open surgery, but requires close follow-up and lifelong cardiac care. Why This Matters For India's Heart-Care Landscape Valvular heart disease (VHD) remains common in India, driven by both rheumatic and degenerative causes. A recent review highlights persistent burdens of VHD across Asia and India, with mitral involvement frequently associated with pulmonary hypertension and heart failure. Broadly, cardiovascular diseases are the leading cause of death globally and account for a large and growing share of non-communicable disease mortality in India. Estimates place the pooled prevalence of cardiovascular disease among Indian adults at about 11%, and national data show that CVD causes a substantial share of deaths in middle and older age groups. These trends make accessible, advanced valve therapies an important public-health priority - not to replace prevention, but as a necessary option for those who need it. (PMC, World Health Organization) Limitations And The Road Ahead Will the Batman Procedure become routine? "It will likely remain a rare, last-resort option for select cases," Dr Rao says. That's realistic: barriers include high device and procedural costs, the need for operator training, and availability of round-the-clock multidisciplinary teams. Evidence remains limited to case series and registry data for many electrosurgical mitral techniques, so broader adoption will depend on careful outcome reporting and training programs. Meanwhile, expanding basic valve-disease detection, timely referrals, and equitable access to advanced cardiac centres must proceed in parallel. Disclaimer: This content including advice provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.
Business Standard
5 days ago
- Business Standard
Pioneering 'Batman Procedure' Offers New Hope to High-Risk Heart Patients
VMPL New Delhi [India], August 8: Doctors at Rajasthan Hospital Limited (RHL), Jaipur have successfully performed India's first electrosurgical valve-in-valve mitral procedure, informally called the "Batman Procedure", giving a 74-year-old woman from Srinagar a new lease on life. Fatima Bano, who had previously undergone open-heart surgery to replace two valves, was once again facing heart failure. Medical investigations revealed her mitral valve was failing, but her advanced age and health condition made her too high-risk for another conventional open-heart surgery, according to specialists at Srinagar and AIIMS, New Delhi. With her condition worsening and traditional surgery deemed too risky, her family turned to Dr. Ravinder Singh Rao, Chairman, RHL Heart Centre & Head - TAVI Program. Dr. Rao and his team performed the complex procedure using an advanced electrosurgical technique. Using a minimally invasive catheter-based approach, Dr. Rao's team employed precision electrosurgical tools, including a fine electrified wire, to precisely open part of the malfunctioning mitral valve and implant a new one, all without opening the chest. This complex but swift procedure, rarely attempted in such high-risk patients, enabled Fatima to walk within days and return home to her routine life shortly after. "This case proves that even elderly, high-risk patients can receive transformative treatment with the right tools and expertise," said Dr. Rao. This case represents a significant milestone in India's cardiovascular care landscape: the nation's first electrosurgical valve-in-valve intervention for a failed mitral valve in a previously operated patient. The procedure demonstrates the possibility of safely treating complex heart valve disease in elderly, high-risk patients once deemed inoperable.
